Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor. It effectively inhibits Flt1, KDR, Flt4, PDGFRα, PDGFRβ, and c-Kit, making it a valuable tool for angiogenesis and cancer research.
- Potent inhibition of VEGF-stimulated proliferation and KDR phosphorylation in human umbilical vein endothelial cells.
- Reduces vessel area, length, and branching in in vitro vessel sprouting models.
- Ablates experimental angiogenesis and inhibits endochondral ossification in vivo.
- Inhibits growth of various human tumor xenografts in athymic mice.
- Induces microvessel density reduction and vascular regression in tumors.
- Actively investigated in clinical trials for various cancer types.